Dr. Martens PLC

Director's Dealing • Jul 17, 2023

National Storage Mechanism | Additional information

RNS Number : 1301G

Dr. Martens PLC

17 July 2023

Dr. Martens plc (the 'Company')

Director/PDMR Shareholding

Notification of Transactions by Directors/Persons Discharging Managerial Responsibility

The Company announces that it has been notified that Kenny Wilson, Chief Executive Officer and PDMR, purchased 309,948 ordinary shares of 1 pence each in the Company ('Ordinary Shares') on 14 July 2023 at a price of £1.290535 per Ordinary Share.

The relevant notification, set out below, is provided in accordance with the requirements of Article 19 of the UK Market Abuse Regulation.

1

Details of the person discharging managerial responsibilities/person closely associated

a)

Name

Kenny Wilson

2

Reason for the notification

a)

Position/status

PDMR (Chief Executive Officer)

b)

Initial notification/Amendment

Initial notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Dr. Martens plc

b)

LEI

213800QPT8YM6NQZPH28

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument

Identification code

Ordinary shares of GBP 0.01

ISIN: GB00BL6NGV24

b)

Nature of the transaction

Purchase of Ordinary Shares

c)

Price(s) and volume(s)

	Price(s)	Volume(s)
	£1.290535	309,948

d)

Aggregated information

-	Aggregated volume
-	Price

Single transaction

e)

Date of the transaction

14 July 2023

f)

Place of the transaction

London Stock Exchange (XLON)

For further information please contact:

Bethany Barnes

Director of Investor Relations

bethany.barnes@drmartens.com

+4478 2518 7465

Paul Rolling

Assistant Company Secretary

paul.rolling@drmartens.com

+4475 8424 3562

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

DSHUSSVROKUBAAR